| Literature DB >> 26846896 |
Shuhei Nomura1, Marta Blangiardo2, Masaharu Tsubokura3, Akihiko Ozaki4, Tomohiro Morita5, Susan Hodgson2.
Abstract
OBJECTIVE: Japan's 2011 Fukushima Daiichi Nuclear Power Plant incident required the evacuation of over a million people, creating a large displaced population with potentially increased vulnerability in terms of chronic health conditions. We assessed the long-term impact of evacuation on diabetes, hyperlipidaemia and hypertension. PARTICIPANTS: We considered participants in annual public health check-ups from 2008 to 2014, administrated by Minamisoma City and Soma City, located about 10-50 km from the Fukushima nuclear plant.Entities:
Keywords: EPIDEMIOLOGY; PUBLIC HEALTH
Mesh:
Year: 2016 PMID: 26846896 PMCID: PMC4746456 DOI: 10.1136/bmjopen-2015-010080
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Geographical location of Minamisoma City and Soma City. The red circles show the geographical distribution of the health check-up participants in 2010, where the circles are proportional to the number of participants living in each district. The compulsory evacuation zone is divided into the (1) difficult-to-return zone (in green), where the annual dose of radiation is expected to be 50 mSv or more and people are not allowed to return home until at least March 2017; (2) no-residence zone (in yellow), where the annual dose is expected to be 20–50 mSv and people can temporarily return home to the area, but staying overnight is prohibited and (3) zone being prepared for lifting of the evacuation order (in blue), where the annual dose is expected to be <20 mSv and people can temporarily return home to the area, but staying overnight is prohibited.
Comparisons of subject characteristics between evacuees and non-evacuees/temporary-evacuees
| Baseline (2008–2010) | 2011 | 2012 | 2013 | 2014 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Evacuees | Non-evacuees/temporary-evacuees | Evacuees | Non-evacuees/temporary-evacuees | Evacuees | Non-evacuees/temporary-evacuees | Evacuees | Non-evacuees/temporary-evacuees | Evacuees | Non-evacuees/temporary-evacuees | |
| City of residence (N) | ||||||||||
| Minamisoma | 960 | 2818 | 216 | 832 | 627 | 1925 | 657 | 2055 | 617 | 1990 |
| Soma | 0 | 2628 | 0 | 2038 | 0 | 1961 | 0 | 1625 | 0 | 1601 |
| Total | 960 | 5446 | 216 | 2870 | 627 | 3886 | 657 | 3680 | 617 | 3591 |
| Demographic characteristics | ||||||||||
| Age in years (mean, SD) | 62.0 (6.6) | 62.4 (7.1) | 64.9 (6.3) | 64.8 (7.3) | 65.3 (6.4) | 65.3 (6.9) | 65.5 (6.5) | 65.7 (6.6) | 66.0 (6.3) | 66.3 (6.3) |
| Gender (N, %) | ||||||||||
| Male | 404 (41.9) | 2203 (40.5) | 95 (44.0) | 1169 (40.7) | 267 (42.6) | 1578 (40.6) | 281 (42.8) | 1459 (39.7) | 254 (41.2) | 1375 (38.3) |
| Female | 556 (58.1) | 3243 (59.5) | 121 (56.0) | 1701 (59.3) | 360 (57.4) | 2308 (59.4) | 376 (57.2) | 2221 (60.4) | 363 (58.8) | 2216 (61.7) |
| Clinical characteristics (mean, SD) | ||||||||||
| BMI (kg/m2) | 23.6 (3.2) | 23.5 (3.3) | 24.0 (3.4) | 23.6 (3.3) | 24.2 (3.3)*** | 23.6 (3.4)*** | 24.0 (3.3)** | 23.6 (3.4)** | 23.7 (3.4)* | 23.4 (3.4)* |
| Systolic blood pressure (mm Hg) | 130.5 (16.1) | 130.7 (16.3) | 130.0 (14.6) | 131.7 (16.0) | 128.9 (15.5)* | 130.7 (16.2)* | 128.0 (14.6) | 128.7 (15.2) | 126.5 (14.1)** | 128.4 (14.8)** |
| Diastolic blood pressure (mm Hg) | 77.5 (9.5) | 77.5 (9.7) | 78.0 (11.3) | 79.0 (10.2) | 76.7 (10.2) | 76.9 (10.3) | 76.3 (9.2) | 75.7 (9.8) | 74.6 (9.3) | 75.1 (9.6) |
| HbA1c (%) | 5.5 (0.6) | 5.5 (0.6) | 5.4 (0.5) | 5.5 (0.6) | 5.6 (0.5) | 5.6 (0.6) | 5.7 (0.6) | 5.7 (0.6) | 5.6 (0.6) | 5.6 (0.6) |
| HDL-C (mg/dL) | 61.4 (14.4) | 61.4 (14.8) | 59.8 (14.5) | 60.9 (14.7) | 56.2 (13.2)*** | 58.8 (14.3)*** | 57.9 (13.9)** | 59.6 (14.3)** | 58.1 (13.8)*** | 60.3 (14.8)*** |
| LDL-C (mg/dL) | 124.9 (30.0) | 125.4 (31.0) | 126.5 (30.9) | 124.4 (31.1) | 120.0 (31.1) | 122.2 (31.0) | 123.5 (30.5) | 124.8 (31.0) | 121.0 (29.7)** | 124.8 (31.2)** |
| ALT/GPT (IU/L) | 22.0 (13.3) | 22.7 (18.5) | 23.3 (16.5) | 24.7 (17.7) | 24.2 (16.4) | 23.4 (18.2) | 23.0 (16.6) | 22.1 (19.3) | 22.8 (16.4) | 22.1 (14.6) |
| AST/GOT (IU/L) | 24.8 (11.5) | 25.1 (11.9) | 24.8 (8.7) | 26.4 (15.0) | 26.4 (13.9) | 25.7 (12.2) | 25.1 (12.2) | 24.9 (15.6) | 24.6 (10.9) | 24.8 (14.7) |
| γ-GTP (IU/L) | 34.0 (40.9) | 37.4 (51.4) | 35.8 (42.4) | 39.3 (56.7) | 38.6 (43.8) | 36.6 (44.9) | 36.8 (51.2) | 36.4 (56.4) | 34.5 (63.7) | 35.8 (55.2) |
| Urine protein (N, % of positive) | 16 (1.7) | 115 (2.1) | 3 (1.4) | 58 (2.0) | 6 (1.0) | 64 (1.7) | 13 (2.0) | 59 (1.6) | 8 (1.3) | 68 (1.9) |
| Urine occult blood (N, % of positive) | 55 (5.7) | 319 (5.9) | 20 (9.3) | 209 (7.6) | 17 (2.7)* | 184 (4.8)* | 30 (4.6) | 185 (5.1) | 30 (4.9) | 163 (4.6) |
| Urine glucose (N, % of positive) | 19 (2.0) | 130 (2.4) | 2 (0.9) | 60 (2.1) | 8 (1.3) | 89 (2.3) | 10 (1.5) | 74 (2.0) | 14 (2.3) | 68 (1.9) |
| Medical characteristics of interests (N, %) | ||||||||||
| Presence of diseases | ||||||||||
| Diabetes | 74 (7.7) | 415 (7.7) | 20 (9.3) | 226 (8.0) | 64 (10.2) | 368 (9.5) | 86 (13.1) | 423 (11.6) | 84 (13.6) | 399 (11.2) |
| Hyperlipidaemia | 430 (44.8) | 2390 (44.3) | 109 (50.5) | 1290 (45.2) | 336 (53.6)** | 1815 (46.8)** | 394 (60.0)*** | 1877 (51.2)*** | 341 (55.3) | 1874 (52.6) |
| Hypertension | 437 (45.5) | 2463 (45.3) | 112 (51.9) | 1506 (52.6) | 333 (53.1) | 2020 (52.1) | 366 (55.7)* | 1888 (51.3)* | 297 (48.1) | 1758 (49.2) |
*p<0.05, **p<0.01, ***p<0.001 for evacuees versus non-evacuees/temporary-evacuees: Un-paired t test for continuous outcomes and χ2 test for categorical outcomes.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
Age-adjusted pre-incident and post-incident relative risk of the diseases (versus baseline (2008–2010))
| Evacuees | Non-evacuees/ temporary-evacuees | p Value of the difference in row | |
|---|---|---|---|
| Diabetes | |||
| 2011 | 1.12 (0.70 to 1.79) | 0.94 (0.81 to 1.10) | 0.5 |
| 2012 | 1.21 (0.88 to 1.67) | 1.11 (0.97 to 1.27) | 0.6 |
| 2013 | 1.55 (1.15 to 2.09)** | 1.33 (1.17 to 1.52)*** | 0.3 |
| 2014 | 1.60 (1.18 to 2.16)** | 1.27 (1.11 to 1.45)*** | 0.1 |
| Hyperlipidaemia | |||
| 2011 | 1.10 (0.94 to 1.27) | 1.00 (0.95 to 1.05) | 0.3 |
| 2012 | 1.16 (1.05 to 1.29)** | 1.03 (0.98 to 1.08) | <0.05 |
| 2013 | 1.30 (1.18 to 1.43)*** | 1.12 (1.07 to 1.17)*** | <0.01 |
| 2014 | 1.20 (1.08 to 1.32)** | 1.14 (1.09 to 1.20)** | 0.6 |
| Hypertension | |||
| 2011 | 1.05 (0.91 to 1.21) | 1.05 (1.01 to 1.10) | 1.0 |
| 2012 | 1.04 (0.94 to 1.14) | 1.03 (0.99 to 1.07) | 1.0 |
| 2013 | 1.10 (1.00 to 1.21)* | 1.01 (0.97 to 1.05) | 0.1 |
| 2014 | 0.94 (0.85 to 1.05) | 0.95 (0.91 to 0.99)* | 0.8 |
*p<0.05, **p<0.01, ***p<0.001 for given year versus baseline (2008–2010), adjusted for age.
Random-effects regression model: OR (95% CI)
| Variable | Diabetes† | Hyperlipidaemia‡ | Hypertension§ |
|---|---|---|---|
| Demographic characteristics | |||
| Evacuation status | |||
| Non-evacuees/temporary-evacuees | 1.00 | 1.00 | 1.00 |
| Evacuees | 1.14 (0.96 to 1.35) | 1.18 (1.06 to 1.32)** | 0.97 (0.86 to 1.09) |
| Year | |||
| 2012 | 1.00 | 1.00 | 1.00 |
| 2013 | 1.27 (1.10 to 1.47)** | 1.09 (0.99 to 1.19) | 0.95 (0.86 to 1.04) |
| 2014 | 1.23 (1.06 to 1.43)** | 1.19 (1.08 to 1.30)*** | 0.80 (0.73 to 0.88)*** |
| City | |||
| Minamisoma | 1.00 | 1.00 | 1.00 |
| Soma | 1.08 (0.95 to 1.23) | 0.86 (0.79 to 0.93)*** | 1.00 (0.92 to 1.09) |
| Age in years | |||
| (40–65) | 1.00 | 1.00 | 1.00 |
| (65–74) | 1.29 (1.12 to 1.48)*** | 1.13 (1.04 to 1.22)** | 2.47 (2.27 to 2.69)*** |
| Gender | |||
| Male | 1.00 | 1.00 | 1.00 |
| Female | 0.43 (0.37 to 0.49)*** | 1.91 (1.75 to 2.10)*** | 0.71 (0.65 to 0.79)*** |
| Clinical characteristics | |||
| BMI | 1.13 (1.11 to 1.15)*** | 1.07 (1.06 to 1.09)*** | 1.18 (1.17 to 1.2)*** |
| HbA1c (%) | – | 1.61 (1.48 to 1.75)*** | – |
| γ-GTP (IU/L) | – | – | 1.00 (1.00 to 1.00)*** |
| Urine protein | |||
| Negative/trace | 1.00 | – | 1.00 |
| Positive | 2.96 (2.16 to 4.05)*** | – | 2.21 (1.56 to 3.13)*** |
| Medical records | |||
| Use of medicines | |||
| Diabetes | |||
| No | – | 1.00 | 1.00 |
| Yes | – | 0.91 (0.77 to 1.07) | 1.45 (1.24 to 1.69)*** |
| Hyperlipidaemia | |||
| No | 1.00 | – | 1.00 |
| Yes | 2.15 (1.89 to 2.45)*** | – | 1.49 (1.36 to 1.63)*** |
| Hypertension | |||
| No | 1.00 | 1.00 | – |
| Yes | 1.49 (1.31 to 1.69)*** | 1.07 (0.99 to 1.16) | – |
| Family disease history | |||
| No | 1.00 | 1.00 | 1.00 |
| Yes | 3.49 (3.08 to 3.96)*** | 4.45 (3.35 to 5.89)*** | 3.12 (2.87 to 3.38)*** |
| Lifestyle | |||
| Tobacco use | |||
| No | 1.00 | 1.00 | 1.00 |
| Yes | 1.26 (1.06 to 1.51)* | 0.95 (0.84 to 1.08) | 0.74 (0.65 to 0.84)*** |
| Alcohol consumption | |||
| None/rarely | 1.00 | 1.00 | 1.00 |
| Sometimes | 0.81 (0.69 to 0.96)* | 0.94 (0.85 to 1.03) | 1.09 (0.99 to 1.21) |
| Every day | 0.68 (0.57 to 0.80)*** | 0.56 (0.50 to 0.62)*** | 1.72 (1.53 to 1.94)*** |
| Low intensity exercise (Q3)¶ | |||
| No | 1.00 | – | – |
| Yes | 1.27 (1.12 to 1.43)*** | – | – |
| Eating speed (Q10)†† | |||
| Normal | – | – | 1.00 |
| Fast | – | – | 0.90 (0.82 to 0.99)* |
| Slow | – | – | 0.72 (0.63 to 0.84)*** |
*p<0.05, **p<0.01, ***p<0.001, adjusted for covariates.
†Surgical history of oesophagus/stomach was also adjusted (data not shown).
‡Surgical history of oesophagus/stomach and treatment history of heart disease, kidney disease, liver disease and blood disease were also adjusted (data not shown).
§Treatment history of heart disease was also adjusted (data not shown).
¶Q3: Do you walk for at least 1 h every day or have equivalent physical activities in your daily life?
††Q10: How fast do you eat compared to others?
BMI, body mass index; GPT, glutamic pyruvic transaminase; HbA1c, glycated haemoglobin.
Figure 2Box plots for the distribution of radiation levels at non-evacuees’/temporary-evacuees’ residences by disease status. The bar represents the median radiation air dose rate, the box shows the 25th and 75th centiles, whiskers are 1.5 times the IQR, and outliers and extreme outlets are shown by dots and asterisks, respectively.